Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT02718833 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02718833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02718833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 21, 2016
Completion date
December 31, 2027
Enrollment
52 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma